Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.43 |
| ▸ | CBLB | Q13191 | 1/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14883271 | 0.78 | EGLN1 (0.56) | EGLN1ALDH1A1EGFRMAP3K5 | |
| SCHEMBL6368422 | 0.78 | PYGL (0.51) | EGLN1GRNSORT1 | |
| SCHEMBL27755828 | 0.78 | KDM4C (0.45) | MEN1KMT2AKDM4CEGLN1 | |
| SCHEMBL7332048 | 0.77 | ITGB2 (0.50) | MEN1KMT2AEGLN1ALDH1A1EGFR | |
| SCHEMBL27467115 | 0.77 | CHRNA7 (0.46) | MEN1KMT2AEGLN1APOBEC3GMAP3K5 | |
| SCHEMBL4560488 | 0.76 | EGLN1 (0.49) | EGLN1EGFRMAP3K5CBLB | |
| SCHEMBL27482350 | 0.76 | EGLN1 (0.46) | MEN1KMT2AEGLN1MAP3K5CBLB | |
| SCHEMBL14876092 | 0.76 | EGLN1 (0.57) | EGLN1EGFR | |
| SCHEMBL18642513 | 0.76 | GCG (0.48) | MEN1KMT2AALDH1A1MAP3K5 | |
| SCHEMBL28216268 | 0.76 | GCG (0.48) | MEN1KMT2AALDH1A1MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101137650-A | 2- [ isoquinoline-S-carbonyl ] amino ] -propionic acid derivatives as inhibitors of factors XI and IX for the treatment of thrombosis | TRANSTECH PHARMA INC (US) | 2008-03-05 | — | — | CN | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | MEN1 3448/4885KMT2A 2112/4885KDM4C 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.